| Title: |
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. |
| Authors: |
On behalf of Grupo Español de Leucemia Mieloide Crónica (GELMC), Grupo Español de Leucemia Mieloide Crónica (GELMC), García-Gutiérrez, Valentín, Piris-Villaespesa, Miguel, Vázquez, Isabel Mata, Payer, Ángel Ramírez, Senín, Alicia, Amustio Díez, Elena, García, Abelardo Bárez, Carrascosa, Guiomar Bautista, Ortí, Guillermo, Ruiz, Beatriz Cuevas, Fernández, Maria Ángeles, Romo, Andres, del Carmen García Garay, María, Milojkovic, Dragana, Claudiani, Simone, Giraldo, Pilar, Guinea, Jose María, De Las Heras Rodríguez, Natalia |
| Source: |
Annals of Hematology; Feb2019, Vol. 98 Issue 2, p321-330, 10p |
| Subject Terms: |
AMINES, CLINICAL trials, COMPARATIVE studies, LONGITUDINAL method, RESEARCH methodology, MEDICAL cooperation, ORGANIC compounds, PROGNOSIS, QUINOLINE, RESEARCH, EVALUATION research, CHRONIC myeloid leukemia, RETROSPECTIVE studies |
| Abstract: |
Bosutinib is a second-generation tyrosine kinase inhibitor (2GTKI) approved at 400 mg once daily (QD) as first-line therapy in patients with chronic myeloid leukemia (CML) patients and at 500 mg QD in patients who are resistant to or intolerant of prior therapy. In clinical practice, bosutinib is often given to patients who have failed imatinib, nilotinib, and dasatinib (i.e., as fourth-line treatment), despite the limited data on its clinical benefit in this setting. We have retrospectively evaluated the results of bosutinib in a series of 62 CML patients who have failed to prior treatment with all three, imatinib, nilotinib, and dasatinib. Median time on TKI treatment before bosutinib start was 105 (9-163) months, and median duration on bosutinib was 9 months (1-30). Overall, probabilities to achieve complete cytogenetic response (CCyR) and major molecular response (MMR) were 25% and 24% respectively. After a median follow-up period of 14 months, the event-free survival and progression-free survival were 68 and 85%, respectively. Sixty-four percent of patients in CCyR at the time of bosutinib start were able to achieve MMR. In contrast, patients without CCyR, probabilities to obtain CCyR and MMR were 25% and 14%. Bosutinib was well tolerated in this heavily pretreated patients' cohort. Pleural effusions and diarrhea were the most frequent grade II-IV side effects, leading to treatment discontinuation in 16% of patients. Bosutinib is an effective treatment option for patients who have failed previous 2GTKIs due to intolerance. However, efficacy seems to be related to the molecular response that the patient achieved prior to bosutinib. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of Hematology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
